$17.4 Billion is the total value of Baker Brothers Advisors's 101 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 22.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $9,452,165,468 | +10.2% | 44,554,162 | 0.0% | 54.48% | +9.8% | |
| BGNE | BeiGene, Ltd.sponsored adr | $2,098,884,503 | +0.9% | 11,668,897 | 0.0% | 12.10% | +0.5% | |
| INCY | Buy | Incyte Corporation | $2,090,035,758 | -7.2% | 36,178,566 | +0.0% | 12.05% | -7.6% |
| ACAD | ACADIA Pharmaceuticals Inc. | $893,298,514 | -13.0% | 42,864,612 | 0.0% | 5.15% | -13.3% | |
| BMRN | BioMarin Pharmaceutical Inc. | $337,130,743 | +2.1% | 3,810,248 | 0.0% | 1.94% | +1.7% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $225,648,303 | -36.8% | 1,545,113 | 0.0% | 1.30% | -37.1% | |
| RYTM | Buy | Rhythm Pharmaceuticals, Inc. | $153,651,351 | +43.4% | 6,702,349 | +3.1% | 0.89% | +42.9% |
| Buy | Roivant Sciences Ltd. | $138,725,357 | +46.0% | 11,877,171 | +26.0% | 0.80% | +45.5% | |
| IMCR | Immunocore Holdings plcads | $130,825,939 | -13.4% | 2,520,731 | 0.0% | 0.75% | -13.8% | |
| Invitae Corporationnote 1.5% 4/1/2028 | $130,372,500 | -3.4% | 300,000,000 | 0.0% | 0.75% | -3.8% | ||
| AKRO | Akero Therapeutics, Inc. | $119,792,559 | +8.3% | 2,368,378 | 0.0% | 0.69% | +7.8% | |
| ABCL | Buy | AbCellera Biologics Inc. | $95,511,286 | -10.1% | 20,763,323 | +26.2% | 0.55% | -10.6% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $89,992,591 | +0.6% | 12,710,818 | 0.0% | 0.52% | +0.2% | |
| REPL | Replimune Group, Inc. | $78,334,371 | -26.3% | 4,578,280 | 0.0% | 0.45% | -26.7% | |
| Entrada Therapeutics, Inc. | $76,879,940 | +4.4% | 4,865,819 | 0.0% | 0.44% | +4.0% | ||
| RVMD | Revolution Medicines, Inc. | $74,500,526 | +3.5% | 2,691,493 | 0.0% | 0.43% | +2.9% | |
| ARGX | Sell | argenx SEsponsored adr | $74,341,830 | -31.9% | 151,215 | -46.0% | 0.43% | -32.3% |
| SWTX | SpringWorks Therapeutics, Inc. | $69,356,440 | -11.8% | 2,999,846 | 0.0% | 0.40% | -12.1% | |
| KYMR | Buy | Kymera Therapeutics, Inc. | $66,030,560 | -34.4% | 4,750,400 | +8.6% | 0.38% | -34.5% |
| IMTX | Immatics N.V. | $65,320,649 | +0.3% | 5,640,816 | 0.0% | 0.38% | -0.3% | |
| MRTX | Mirati Therapeutics, Inc. | $61,410,191 | +20.6% | 1,409,784 | 0.0% | 0.35% | +20.0% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $48,802,352 | +23.4% | 2,809,577 | 0.0% | 0.28% | +22.7% | |
| RARE | Buy | Ultragenyx Pharmaceutical Inc. | $48,717,401 | +34.9% | 1,366,547 | +74.5% | 0.28% | +34.4% |
| DNLI | Buy | Denali Therapeutics Inc. | $47,284,022 | +10.1% | 2,292,003 | +57.5% | 0.27% | +9.6% |
| PRLD | Prelude Therapeutics Inc. | $31,282,616 | -31.3% | 10,123,824 | 0.0% | 0.18% | -31.8% | |
| KOD | Kodiak Sciences Inc. | $31,158,882 | -73.9% | 17,310,490 | 0.0% | 0.18% | -74.0% | |
| NRIX | Nurix Therapeutics, Inc. | $30,513,503 | -21.3% | 3,882,125 | 0.0% | 0.18% | -21.4% | |
| BMEA | Biomea Fusion, Inc. | $29,019,138 | -37.3% | 2,108,949 | 0.0% | 0.17% | -37.7% | |
| IDYA | IDEAYA Biosciences, Inc. | $28,656,079 | +14.8% | 1,062,123 | 0.0% | 0.16% | +14.6% | |
| CERS | Buy | Cerus Corporation | $27,927,992 | -29.3% | 17,239,501 | +7.3% | 0.16% | -29.7% |
| AVTE | Aerovate Therapeutics, Inc. | $26,644,410 | -20.9% | 1,963,479 | 0.0% | 0.15% | -21.0% | |
| IGMS | Buy | IGM Biosciences, Inc. | $26,367,329 | -9.5% | 3,157,764 | +0.0% | 0.15% | -10.1% |
| XENE | Xenon Pharmaceuticals Inc. | $25,675,988 | -11.3% | 751,639 | 0.0% | 0.15% | -11.4% | |
| CABA | Cabaletta Bio, Inc. | $24,260,680 | +17.9% | 1,594,000 | 0.0% | 0.14% | +17.6% | |
| GLUE | Buy | Monte Rosa Therapeutics, Inc. | $23,548,095 | +13.7% | 4,916,095 | +62.6% | 0.14% | +13.3% |
| DBVT | DBV Technologies S.A.sponsored adr | $19,875,399 | -28.4% | 14,614,264 | 0.0% | 0.12% | -28.6% | |
| KRYS | Krystal Biotech, Inc. | $19,712,344 | -1.2% | 169,934 | 0.0% | 0.11% | -0.9% | |
| VERV | Verve Therapeutics, Inc. | $18,783,188 | -29.3% | 1,416,530 | 0.0% | 0.11% | -29.9% | |
| BCYC | Bicycle Therapeutics plcsponsored ads | $16,952,223 | -21.3% | 843,814 | 0.0% | 0.10% | -21.6% | |
| IMVT | New | Immunovant, Inc. | $16,316,096 | – | 425,009 | +100.0% | 0.09% | – |
| COGT | Buy | Cogent Biosciences, Inc. | $12,606,419 | +8.7% | 1,292,966 | +32.0% | 0.07% | +9.0% |
| DAWN | Day One Biopharmaceuticals, Inc. | $12,270,000 | +2.8% | 1,000,000 | 0.0% | 0.07% | +2.9% | |
| Prime Medicine, Inc. | $9,811,566 | -34.9% | 1,028,466 | 0.0% | 0.06% | -34.5% | ||
| RLAY | Relay Therapeutics, Inc. | $9,756,584 | -33.0% | 1,160,117 | 0.0% | 0.06% | -33.3% | |
| 2seventy bio, Inc. | $9,790,302 | -61.3% | 2,497,526 | 0.0% | 0.06% | -61.6% | ||
| PACB | Pacific Biosciences of California, Inc. | $9,416,980 | -37.2% | 1,127,782 | 0.0% | 0.05% | -37.9% | |
| INSM | Insmed Incorporated | $8,660,750 | +19.7% | 343,000 | 0.0% | 0.05% | +19.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $8,556,040 | -15.7% | 10,969,282 | 0.0% | 0.05% | -16.9% | |
| Tango Therapeutics, Inc. | $8,445,000 | +239.2% | 750,000 | 0.0% | 0.05% | +250.0% | ||
| HRTX | Heron Therapeutics, Inc. | $8,375,628 | -11.2% | 8,131,678 | 0.0% | 0.05% | -12.7% | |
| ARVN | New | Arvinas, Inc. | $8,120,767 | – | 413,481 | +100.0% | 0.05% | – |
| TSHA | New | Taysha Gene Therapies, Inc. | $7,915,029 | – | 2,504,756 | +100.0% | 0.05% | – |
| SANA | Sana Biotechnology, Inc. | $7,740,000 | -35.1% | 2,000,000 | 0.0% | 0.04% | -34.8% | |
| SBTX | ARS Pharmaceuticals, Inc. | $7,584,385 | -43.6% | 2,006,451 | 0.0% | 0.04% | -43.6% | |
| BLUE | bluebird bio, Inc. | $7,599,134 | -7.6% | 2,499,715 | 0.0% | 0.04% | -8.3% | |
| TScan Therapeutics, Inc. | $7,129,068 | +2.4% | 2,784,792 | 0.0% | 0.04% | +2.5% | ||
| New | Sagimet Biosciences Inc. | $7,175,159 | – | 815,359 | +100.0% | 0.04% | – | |
| GERN | Geron Corporation | $6,489,795 | -34.0% | 3,061,224 | 0.0% | 0.04% | -35.1% | |
| ATHA | Athira Pharma, Inc. | $6,370,690 | -31.5% | 3,153,807 | 0.0% | 0.04% | -31.5% | |
| New | Invitae Corporationseries a 4.5% 3/15/2028 | $6,208,368 | – | 9,274,000 | +100.0% | 0.04% | – | |
| ALEC | Alector, Inc. | $6,252,234 | +7.8% | 964,851 | 0.0% | 0.04% | +5.9% | |
| EWTX | Buy | Edgewise Therapeutics, Inc. | $6,014,775 | +55.2% | 1,049,699 | +109.9% | 0.04% | +59.1% |
| MIRM | New | Mirum Pharmaceuticals, Inc. | $6,019,042 | – | 190,476 | +100.0% | 0.04% | – |
| SMMT | Sell | Summit Therapeutics Inc. | $5,872,685 | -62.9% | 3,140,473 | -50.2% | 0.03% | -63.0% |
| STOK | Sell | Stoke Therapeutics, Inc. | $5,854,505 | -74.1% | 1,485,915 | -30.2% | 0.03% | -74.0% |
| HOOK | Buy | HOOKIPA Pharma Inc. | $4,968,285 | +27.6% | 8,065,398 | +82.2% | 0.03% | +26.1% |
| Aadi Bioscience, Inc. | $4,791,252 | -29.2% | 989,928 | 0.0% | 0.03% | -28.2% | ||
| CELC | New | Celcuity Inc. | $4,894,269 | – | 535,478 | +100.0% | 0.03% | – |
| MORF | New | Morphic Holding, Inc. | $4,943,978 | – | 215,800 | +100.0% | 0.03% | – |
| New | Neoleukin Therapeutics, Inc. | $4,824,585 | – | 1,221,414 | +100.0% | 0.03% | – | |
| OPT | Sell | Opthea Limitedsponsored ads | $4,687,532 | -37.8% | 2,690,891 | -0.0% | 0.03% | -38.6% |
| NTRA | Natera, Inc. | $4,425,000 | -9.1% | 100,000 | 0.0% | 0.03% | -7.1% | |
| DSGN | Buy | Design Therapeutics, Inc. | $3,540,000 | +12.4% | 1,500,000 | +200.0% | 0.02% | +11.1% |
| PRAX | Praxis Precision Medicines, Inc. | $3,214,655 | +48.7% | 1,879,915 | 0.0% | 0.02% | +46.2% | |
| CMPX | Compass Therapeutics, Inc. | $3,068,531 | -38.1% | 1,557,630 | 0.0% | 0.02% | -37.9% | |
| GRCL | Gracell Biotechnologies Inc.sponsored ads | $2,880,000 | -24.4% | 1,000,000 | 0.0% | 0.02% | -22.7% | |
| Sell | Talis Biomedical Corporation | $2,933,024 | -19.9% | 508,323 | -93.3% | 0.02% | -19.0% | |
| Sell | Sera Prognostics, Inc. | $2,818,536 | -51.9% | 1,515,342 | -14.7% | 0.02% | -52.9% | |
| PCVX | Vaxcyte, Inc. | $2,492,157 | +2.1% | 48,885 | 0.0% | 0.01% | 0.0% | |
| Buy | KALA BIO, Inc. | $2,372,856 | +39.9% | 266,613 | +129.4% | 0.01% | +40.0% | |
| XNCR | Xencor, Inc. | $2,481,009 | -19.3% | 123,127 | 0.0% | 0.01% | -22.2% | |
| IPSC | Century Therapeutics, Inc. | $2,298,680 | -36.7% | 1,149,340 | 0.0% | 0.01% | -38.1% | |
| ACHL | Achilles Therapeutics plcsponsored ads | $2,326,750 | -3.7% | 2,557,149 | 0.0% | 0.01% | -7.1% | |
| TIL | Sell | Instil Bio, Inc. | $2,013,481 | -30.7% | 4,704,395 | -10.8% | 0.01% | -29.4% |
| ISR | Buy | Perspective Therapeutics, Inc. | $2,090,987 | +35.0% | 7,639,703 | +229.4% | 0.01% | +33.3% |
| AFMD | Sell | Affimed N.V. | $2,126,007 | -46.1% | 4,448,644 | -32.6% | 0.01% | -47.8% |
| ANAB | Sell | AnaptysBio, Inc. | $1,907,298 | -87.9% | 106,197 | -86.3% | 0.01% | -87.9% |
| PMVP | PMV Pharmaceuticals, Inc. | $1,977,227 | -1.9% | 322,024 | 0.0% | 0.01% | -8.3% | |
| PNT | Sell | POINT Biopharma Global Inc. | $1,667,287 | -84.3% | 249,968 | -78.6% | 0.01% | -83.6% |
| ALGS | Aligos Therapeutics, Inc. | $1,551,071 | -23.1% | 2,076,400 | 0.0% | 0.01% | -25.0% | |
| ITOS | iTeos Therapeutics, Inc. | $1,646,289 | -17.3% | 150,346 | 0.0% | 0.01% | -25.0% | |
| Leap Therapeutics, Inc. | $1,617,602 | -55.9% | 1,172,175 | 0.0% | 0.01% | -57.1% | ||
| VOR | Vor Biopharma Inc. | $1,343,758 | -31.4% | 633,848 | 0.0% | 0.01% | -27.3% | |
| MRSN | Mersana Therapeutics, Inc. | $1,379,366 | -61.4% | 1,086,115 | 0.0% | 0.01% | -61.9% | |
| RNA | Sell | Avidity Biosciences, Inc. | $1,061,294 | -88.0% | 166,347 | -79.2% | 0.01% | -88.2% |
| NVTA | Sell | Invitae Corporation | $1,067,903 | -89.4% | 1,764,546 | -80.1% | 0.01% | -89.7% |
| BCEL | Atreca, Inc. | $922,050 | -73.4% | 3,532,760 | 0.0% | 0.01% | -75.0% | |
| GTH | Genetron Holdings Limitedads | $369,754 | -12.7% | 455,306 | 0.0% | 0.00% | 0.0% | |
| TARA | Protara Therapeutics, Inc. | $333,451 | -30.1% | 199,671 | 0.0% | 0.00% | -33.3% | |
| FHTX | Foghorn Therapeutics Inc. | $225,135 | -29.0% | 45,027 | 0.0% | 0.00% | -50.0% | |
| Surrozen, Inc.w exp 8/11/2026 | $34,250 | -25.5% | 833,333 | 0.0% | 0.00% | – | ||
| VINC | Exit | Vincerx Pharma, Inc. | $0 | – | -225,579 | -100.0% | -0.00% | – |
| NKTX | Exit | Nkarta, Inc. | $0 | – | -271,329 | -100.0% | -0.00% | – |
| FGEN | Exit | FibroGen, Inc. | $0 | – | -238,084 | -100.0% | -0.00% | – |
| AGLE | Exit | Aeglea BioTherapeutics, Inc. | $0 | – | -3,410,106 | -100.0% | -0.01% | – |
| VERA | Exit | Vera Therapeutics, Inc.cl a | $0 | – | -146,464 | -100.0% | -0.01% | – |
| NLTX | Exit | Neoleukin Therapeutics, Inc. | $0 | – | -3,821,740 | -100.0% | -0.02% | – |
| ARAV | Exit | Aravive, Inc. | $0 | – | -3,261,224 | -100.0% | -0.02% | – |
| MREO | Exit | Mereo BioPharma Group PLCsponsored ads | $0 | – | -3,554,979 | -100.0% | -0.03% | – |
| MGNX | Exit | MacroGenics, Inc. | $0 | – | -892,579 | -100.0% | -0.03% | – |
| ALLO | Exit | Allogene Therapeutics, Inc. | $0 | – | -1,576,901 | -100.0% | -0.04% | – |
| FATE | Exit | Fate Therapeutics, Inc. | $0 | – | -1,671,717 | -100.0% | -0.05% | – |
| Exit | Verastem, Inc. | $0 | – | -1,336,485 | -100.0% | -0.06% | – | |
| IMGN | Exit | ImmunoGen, Inc. | $0 | – | -1,520,097 | -100.0% | -0.17% | – |
| Exit | DICE Therapeutics, Inc. | $0 | – | -1,035,786 | -100.0% | -0.28% | – | |
| KDNY | Exit | Chinook Therapeutics, Inc. | $0 | – | -1,455,202 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.